Evoke Pharma Company Leadership
| EVOK Stock | USD 4.08 0.19 4.45% |
Evoke Pharma employs about 4 people. The company is managed by 8 executives with a total tenure of roughly 42 years, averaging almost 5.0 years of service per executive, having 0.5 employees per reported executive. Inspection of Evoke Pharma's management performance can provide insight into the company performance.
| David Gonyer CEO CEO, Founder, Director |
| Matthew DOnofrio President Executive Vice President Chief Business Officer Treasurer, Secretary , |
Evoke |
Evoke Pharma's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Evoke Pharma's future performance. Based on our forecasts, it is anticipated that Evoke will maintain a workforce of about 7 employees by January 2025.Evoke Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.335) % which means that it has lost $0.335 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4991) %, meaning that it created substantial loss on money invested by shareholders. Evoke Pharma's management efficiency ratios could be used to measure how well Evoke Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 3.17 this year, although the value of Return On Tangible Assets will most likely fall to (1.16). At this time, Evoke Pharma's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to rise to about 101.4 K this year, although the value of Total Current Liabilities will most likely fall to about 2.3 M.The value of Common Stock Shares Outstanding is expected to slide to about 264.7 K. The value of Net Loss is expected to slide to about (7.8 M)
Evoke Pharma Workforce Comparison
Evoke Pharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 6,501. Evoke Pharma adds roughly 4.0 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (0.71) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.48) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.48. Evoke Pharma Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evoke Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evoke Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Evoke Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 2.5 | 5 | 2 | 76,250 | 23,500 |
| 2020-12-01 | 0.3333 | 2 | 6 | 118,000 | 236,000 |
| 2019-06-01 | 1.5385 | 20 | 13 | 1,849,812 | 1,017,905 |
| 2016-06-01 | 0.3333 | 6 | 18 | 114,000 | 453,664 |
| 2016-03-01 | 2.0 | 12 | 6 | 585,561 | 483,500 |
| 2015-09-01 | 0.6667 | 2 | 3 | 6,017 | 12,240 |
| 2015-06-01 | 1.0 | 6 | 6 | 54,000 | 51,020 |
| 2014-09-01 | 3.0 | 3 | 1 | 10,506 | 5,250 |
| 2013-09-01 | 1.3333 | 28 | 21 | 10,339,199 | 2,923,574 |
Evoke Pharma Notable Stakeholders
An Evoke Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Evoke Pharma often face trade-offs trying to please all of them. Evoke Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Evoke Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David RPh | CEO CoFounder | Profile | |
| David Gonyer | CEO, Founder, Director | Profile | |
| Matthew MBA | President CoFounder | Profile | |
| Matthew DOnofrio | Executive Vice President Chief Business Officer Treasurer, Secretary , | Profile | |
| Mark CPA | Chief Officer | Profile | |
| DMD MD | Chief Officer | Profile | |
| Christopher Quesenberry | Chief Gimoti | Profile | |
| Marilyn Carlson | Chief Medical Officer | Profile |
About Evoke Pharma Management Performance
The success or failure of an entity such as Evoke Pharma often depends on how effective the management is. Evoke Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Evoke management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Evoke management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.10) | (1.16) | |
| Return On Capital Employed | (1.84) | (1.93) | |
| Return On Assets | (1.10) | (1.16) | |
| Return On Equity | 3.02 | 3.17 |
Evoke Pharma Workforce Analysis
Traditionally, organizations such as Evoke Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Evoke Pharma within its industry.Evoke Pharma Manpower Efficiency
Return on Evoke Pharma Manpower
| Revenue Per Employee | 1.3M | |
| Revenue Per Executive | 647.6K | |
| Net Loss Per Employee | 1.9M | |
| Net Loss Per Executive | 974K | |
| Working Capital Per Employee | 947.8K | |
| Working Capital Per Executive | 473.9K |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.13) | Revenue Per Share 7.792 | Quarterly Revenue Growth 0.698 | Return On Assets (0.34) | Return On Equity (3.50) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.